Proteomics International Laboratories

Proteomics International Laboratories EBIT Margin

The EBIT Margin (Operating Margin) of Proteomics International Laboratories (PIQ.AX) as of Oct 28, 2026 is -4,275.74 %. In the previous year, EBIT Margin (Operating Margin) was -1,105.67 % — a change of 286.71% (lower).

EBIT Margin

-4,275.74 %

YoY

286.71%

Last updated:

EBIT Margin (Operating Margin) of Proteomics International Laboratories is 2026 -4,275.74 % . EBIT Margin (Operating Margin) of Proteomics International Laboratories was 2025 -1,105.67 % . It decreases by 286.71% lower compared to the previous year.

Proteomics International Laboratories's operating (EBIT) margin stands at -4,275.7%, down from -334.2% several years earlier.

The Proteomics International Laboratories EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2019
-126.02 AUD
Jan 1, 2020
-140.42 AUD
Jan 1, 2021
-235.17 AUD
Jan 1, 2022
-334.20 AUD
Jan 1, 2023
-871.59 AUD
Jan 1, 2024
-1,022.79 AUD
Jan 1, 2025
-1,105.67 AUD
Jan 1, 2026
-4,275.74 AUD
The Proteomics International Laboratories EBIT Margin history
YEAREBIT MarginYoY
-4,275.74 %+286.71%
-1,105.67 %+8.10%
-1,022.79 %+17.35%
-871.59 %+160.80%
-334.20 %+42.11%
-235.17 %+67.48%
-140.42 %+11.42%
-126.02 %-36.85%
-199.55 %-124.99%
798.54 %-441.78%
-233.64 %+62.28%
-143.98 %+654.83%
-19.07 %+11,739.54%
-0.16 %-67.18%
-0.49 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Proteomics International Laboratories Stock analysis

What does Proteomics International Laboratories do? Proteomics International Laboratories Ltd is a medical technology company based in Nedlands, Western Australia, listed on the stock exchange in April 2015. Operating within the health care sector, the firm specializes in predictive diagnostics and bio-analytical services, focusing on the study of protein structure and function. It develops and commercializes diagnostic tests for chronic diseases, particularly diabetic kidney disease. The company operates three unified business units: PromarkerD, which offers a blood test to assess DKD risk in type 2 diabetes patients; Diagnostics, which utilizes the Promarker platform to discover and validate protein biomarkers; and Analytical Services, which employs a proteomics-based technology platform to test and validate the protein composition of various products. Proteomics International Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Proteomics International Laboratories stock

EBIT Margin (Operating Margin) of Proteomics International Laboratories is -4,275.74 % in 2026.

EBIT Margin (Operating Margin) of Proteomics International Laboratories changed from -1,105.67 % to -4,275.74 %, representing a 286.71% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Proteomics International Laboratories since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Proteomics International Laboratories with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Proteomics International Laboratories

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Proteomics International Laboratories